CFB and bilirubin encephalopathy: The susceptibility of newborns and their immature nerve cells to BIND, together with the deregulation of microglial immune response by Bf with early and ensuing impacts in degenerative processes, suggest immunomodulation as a promising therapeutic strategy in neonates in risk for bilirubin encephalopathy and critical outcomes.